Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting the underlying drivers of metabolic decline and dysfunction, today announced that a poster featuring data from two Phase 1 studies of ATX-304 will be presented at ObesityWeek® 2026, The Obesity Society’s 44th Annual Meeting, taking place November 14-17, 2026, at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

ATX-304 is the first AMPK Network Activator to enter clinical development. ATX-304 increases cellular glucose uptake, mobilization of fat stores, and cellular respiration, resulting in a simultaneous increase in both energy supply and demand. Results presented at ObesityWeek will further characterize the pronounced weight-independent effects on metabolism described in prior clinical and preclinical studies.

“Activation of the full AMPK network has never been successfully achieved in humans. We are excited to build on clinical results first presented at ADA earlier this year and show at ObesityWeek the dose- and time-dependent effects of ATX-304 on lipids, adipose tissue, and energy expenditure,” said James Peyer, PhD, CEO and Founder of Cambrian Bio.

“We believe that patients need novel treatment options for weight management that do not rely solely on greater reductions in caloric intake. By increasing substrate utilization and energy expenditure in peripheral tissues, mechanisms like that of ATX-304 could offer a complementary approach to today’s appetite-suppressing obesity therapies,” said Ruth Thieroff-Ekerdt, MD, Chief Medical Officer and Head of R&D at Cambrian Bio. “The data we are presenting at ObesityWeek further strengthen the clinical foundation for ATX-304 as we prepare for Phase 2 studies and beyond in patients with obesity and overweight.”

Presentation Information:

Positive Metabolic Effects of ATX-304, an AMPK and Mitochondrial Activator, from Two Phase 1 Studies

Poster #: Poster-111

Date/Time: Saturday, November 14, 2026, 7:30–8:30 PM ET

Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center, National Harbor, Maryland

Session: Translational Research & Emerging Metabolic Therapies

Abstracts will be publicly available beginning Saturday, November 14, 2026 at 12:00 PM ET via the ObesityWeek website and app, and in a supplement to the journal Obesity. A copy of the poster will be available on the Cambrian Bio website following our presentation on November 14, 2026.

About Cambrian Bio

Cambrian Bio (Cambrian BioPharma Inc.) is a clinical-stage drug development company focused on developing therapeutics that reverse metabolic decline, with programs targeting critical cellular metabolic sensors, including AMPK and mTOR, that become dysregulated with age and drive chronic disease. To learn more, visit www.CambrianBio.com and follow us on LinkedIn and X.

About ATX-304

ATX-304, being developed by Cambrian Bio, is a first-in-class AMPK Network Activator capable of increasing both cellular energy uptake and mitochondrial respiration, thereby allowing cells to remain in energetic balance while increasing metabolic rate.

The drug is a peripherally restricted, oral small molecule entering Phase 2 clinical trials in obesity and other cardiometabolic diseases. In a human study in adults with obesity and prediabetes, ATX-304 produced statistically significant improvements in lipid metabolism, body composition, and resting metabolic rate. In preclinical studies, ATX-304 demonstrated muscle-sparing weight loss in obese animals, reversal of multiple cardiometabolic diseases, and major improvements in exercise endurance. ATX-304 is an investigational drug and is not approved for use outside of clinical studies.

Media gallery

About The Author
Business Wire